Triplet therapy for prostate cancer

The past 8 years have seen four agents shown to be superior to androgen deprivation therapy (ADT) alone in terms of overall survival when given as doublet therapy with ADT for metastatic castration-sensitive prostate cancer.1–7 In The Lancet, Karim Fizazi and colleagues8 report the findings from the PEACE-1 trial, which provides evidence in support of triplet therapy for metastatic castration-sensitive prostate cancer. The trial enrolled 1173 male patients (aged ≥18 years, across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland) with synchronous (de novo) metastatic hormone-sensitive prostate cancer who received ADT (plus docetaxel in 60% of patients) as standard of care alone, or standard of care with the addition of abiraterone plus prednisone (hereafter referred to as abiraterone), radiotherapy to the primary tumour, or abiraterone plus radiotherapy, in a randomised 2 × 2 factorial design.